Gri Bio Inc (GRI)

$1.96 -0.18 (-8.41%)
Market Cap 4.97M
Revenue (ttm) 0.00
Net Income (ttm) -8.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 202,926
Avg Vol 236,374
Day's Range N/A - N/A
Shares Out 2.50M
Stochastic %K 88%
Beta -1.62
Analysts Strong Sell
Price Target $22.00

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology
Sector: Healthcare
Phone: 619 400 1170
Address:
2223 Avenida de la Playa, Suite 208, LA Jolla, United States
Dirk1969
Dirk1969 Jul. 29 at 7:46 PM
$GRI 2$ ✅📈
0 · Reply
mendez628
mendez628 Jul. 29 at 5:15 PM
$GRI this shit sucks so much lol
0 · Reply
Wildblitz
Wildblitz Jul. 29 at 3:55 PM
$GRI WTF
0 · Reply
faithTrades
faithTrades Jul. 29 at 9:22 AM
$GRI 2.23
0 · Reply
makedatbread88
makedatbread88 Jul. 28 at 2:08 PM
$GRI ****follow me for more winning calls***
0 · Reply
dButterz
dButterz Jul. 28 at 1:14 PM
$GRI
0 · Reply
judgeyoung2
judgeyoung2 Jul. 28 at 1:06 PM
$MTSR $GRI $LLY one of you please give me data this week. thank you
0 · Reply
mendez628
mendez628 Jul. 28 at 12:45 PM
$GRI results this week? Let’s see
0 · Reply
DK25
DK25 Jul. 27 at 11:26 PM
$GRI Will not surprise if when wake up and see this 300-500% plus on Premkt in this week on solid data news
1 · Reply
Panther72
Panther72 Jul. 27 at 10:56 PM
$GRI this is a key week for this stock. I do have a small stake in this. Im prepared for the worst but hoping for best!! Good Luck to you all!
1 · Reply
Latest News on GRI
GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 7 days ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Jul 1, 2025, 8:45 AM EDT - 4 weeks ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Jun 26, 2025, 8:00 AM EDT - 4 weeks ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 21, 2025, 9:15 AM EDT - 2 months ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 16, 2025, 9:15 AM EDT - 2 months ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 15, 2025, 8:35 AM EDT - 2 months ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 8, 2025, 8:45 AM EDT - 2 months ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 2 months ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 16, 2025, 8:35 AM EDT - 3 months ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 2, 2025, 4:05 PM EDT - 4 months ago

GRI Bio Announces Closing of $5.0 Million Public Offering

GRI Bio Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 4 months ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

Apr 1, 2025, 11:07 AM EDT - 4 months ago

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 31, 2025, 8:00 AM EDT - 4 months ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 18, 2025, 9:05 AM EDT - 4 months ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 17, 2025, 8:05 AM EDT - 4 months ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Mar 11, 2025, 8:35 AM EDT - 5 months ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

GRI Bio Announces Reverse Stock Split

Feb 19, 2025, 4:05 PM EST - 5 months ago

GRI Bio Announces Reverse Stock Split

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 5 months ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Dec 23, 2024, 9:00 AM EST - 7 months ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 21, 2024, 8:45 AM EST - 8 months ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Nov 14, 2024, 4:20 PM EST - 9 months ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 24, 2024, 8:30 AM EDT - 9 months ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GRI Bio Announces Exercise of Warrants

Oct 21, 2024, 5:35 PM EDT - 10 months ago

GRI Bio Announces Exercise of Warrants

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Oct 16, 2024, 8:45 AM EDT - 10 months ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 30, 2024, 8:30 AM EDT - 10 months ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 25, 2024, 8:45 AM EDT - 10 months ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:45 AM EDT - 11 months ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GRI Bio to Present at the 2024 European Respiratory Congress

Sep 4, 2024, 8:45 AM EDT - 11 months ago

GRI Bio to Present at the 2024 European Respiratory Congress

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:05 AM EDT - 1 year ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 15, 2024, 9:05 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 11, 2024, 9:20 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

GRI Bio Regains Compliance with Nasdaq

Jul 8, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 2, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

GRI Bio to Present at the 8th Annual IPF Summit

Jul 1, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 8th Annual IPF Summit

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 28, 2024, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $4.0 Million Public Offering

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

Jun 27, 2024, 9:00 AM EDT - 1 year ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 22, 2024, 9:15 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

May 21, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

May 20, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 14, 2024, 9:05 AM EDT - 1 year ago

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 8:00 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

Apr 29, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Apr 25, 2024, 9:15 AM EDT - 1 year ago

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

Apr 16, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

Apr 8, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Apr 1, 2024, 7:35 AM EDT - 1 year ago

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

Mar 28, 2024, 9:00 AM EDT - 1 year ago

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

Mar 14, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

Mar 4, 2024, 8:30 AM EST - 1 year ago

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)

Feb 23, 2024, 7:50 AM EST - 1 year ago

Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)

SINT

Dirk1969
Dirk1969 Jul. 29 at 7:46 PM
$GRI 2$ ✅📈
0 · Reply
mendez628
mendez628 Jul. 29 at 5:15 PM
$GRI this shit sucks so much lol
0 · Reply
Wildblitz
Wildblitz Jul. 29 at 3:55 PM
$GRI WTF
0 · Reply
faithTrades
faithTrades Jul. 29 at 9:22 AM
$GRI 2.23
0 · Reply
makedatbread88
makedatbread88 Jul. 28 at 2:08 PM
$GRI ****follow me for more winning calls***
0 · Reply
dButterz
dButterz Jul. 28 at 1:14 PM
$GRI
0 · Reply
judgeyoung2
judgeyoung2 Jul. 28 at 1:06 PM
$MTSR $GRI $LLY one of you please give me data this week. thank you
0 · Reply
mendez628
mendez628 Jul. 28 at 12:45 PM
$GRI results this week? Let’s see
0 · Reply
DK25
DK25 Jul. 27 at 11:26 PM
$GRI Will not surprise if when wake up and see this 300-500% plus on Premkt in this week on solid data news
1 · Reply
Panther72
Panther72 Jul. 27 at 10:56 PM
$GRI this is a key week for this stock. I do have a small stake in this. Im prepared for the worst but hoping for best!! Good Luck to you all!
1 · Reply
elkhro
elkhro Jul. 27 at 10:09 PM
$GRI surely we should see results this week
1 · Reply
BenedictArthurKnight
BenedictArthurKnight Jul. 27 at 12:36 PM
$GRI the company is compliant and trading at $2 why would they do a RS lol
0 · Reply
Warrent_jr
Warrent_jr Jul. 27 at 10:22 AM
$GRI Personally I see reverse split as the more likely route if they’re eyeing a serious fund raise. KAPA's been burning through cash fast — still too early in the game for any real results to show. GRI might follow a similar path.
0 · Reply
BenedictArthurKnight
BenedictArthurKnight Jul. 26 at 8:43 PM
$GRI one no one is talking about with data imminent 👀 I think we could see a similar move like $KAPA and push for those warrants
0 · Reply
Wildblitz
Wildblitz Jul. 25 at 5:01 PM
$GRI ZZZZZZZZ
0 · Reply
Stockswingalert
Stockswingalert Jul. 25 at 2:42 AM
$GRI daily with a catalyst
1 · Reply
Wildblitz
Wildblitz Jul. 24 at 8:28 PM
$GRI can this turd stay green for a day??
1 · Reply
MGeronimo
MGeronimo Jul. 24 at 7:58 PM
$GRI IN AT 1.98
0 · Reply
elkhro
elkhro Jul. 24 at 6:20 PM
$GRI soon
0 · Reply
madan_shatri
madan_shatri Jul. 24 at 4:34 PM
$GRI Can't push beyond certain mark. Looks like $2 is a pivot. Wouldn't go much away on either side of $2 until the news. Stuck in a channel But holding tight !
0 · Reply
Wildblitz
Wildblitz Jul. 24 at 3:02 AM
$GRI need news to push this!! Dying down here
1 · Reply
mendez628
mendez628 Jul. 23 at 11:50 PM
$GRI data?
1 · Reply